Get Connected:


Latest News

Hepatitis C Drug Cost Variance Highlights AJPB Week in Review
Top articles of the week from The American Journal of Pharmacy Benefits.
FDA awards $23 million to 21 clinical trials of treatments and devices for rare diseases.
Inflectra is the first biosimilar monoclonal antibody approved by the FDA.
Celgene and Agios will collaborate with a technology company to improve diagnostics for patients with acute myeloid leukemia.
Rolofylline could prevent clumps of Tau protein associated with certain cognitive disorders.
Top news of the day from across the healthcare landscape.
Efficacy and safety data shows encouraging results for rucaparib in BRCA-mutation ovarian cancer.
Obstacles exist in making testing and treatment for hepatitis C routine practice in prison.
View More >

From the Journals

This study explores the impact of a Medicare Part D formulary tier change, specifically with respect to branded insulin products, on insulin adherence, hemoglobin A1C, and diabetes-related events in elderly diabetic beneficiaries strategies for selection of appropriate and cost-effective therapy will also be discussed.
This study assesses comparative resource use for patients given a new diagnosis of nonvalvular atrial fibrillation treated with dabigatran or warfarin in a real-world setting.
This retrospective study compared the treatment patterns of ustekinumab with recommended maintenance administration every 12 weeks, with adalimumab and etanercept, administered weekly or every other week, for the treatment of plaque psoriasis.
This study presents the first information available regarding enablement and use by state and area characteristics of electronic prescribing of controlled substances by prescribers and pharmacy systems in from an e-prescribing network.
This manuscript addresses pharmacist understanding of and/or involvement with the Hospital-Acquired Condition Reduction Program (HACRP) at their institutions.
The role of Pharmacy and Therapeutic committees in formulary creations raises concerns.
This study examines variations in overall use, and potentially inappropriate use, of non-warfarin direct-acting oral anticoagulants across sites within the Veterans Health Administration.
Upcoming Partner Events